Brought to you by 
BMS, Novartis to co-promote tegaserod and develop compounds
15 Jun 2012
Executive Summary
Bristol-Myers Squibb will co-develop and co-promote (except in Japan) Novartis's Zelmac (tegaserod) to treat irritable bowel syndrome. In return BMS will give Novartis certain rights to two of its drug candidates, CTLA 4Ig and LEA 29Y, in development to stop rejection of transplanted organs.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS, Novartis to co-promote tegaserod and develop compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice